Limited time. Limited Seats. 29% off.|Foresight ₹1,40,000 ₹99,000 + 18% GST|12 months of accessGet Foresight
All board jobs

Applications closed

This seat is no longer taking applications — closed on 29 October 2026.

The brief stays here for reference. Seats like it open every week.

See live board seats
India ID ExchangeSector-Regulated Independent Director First-timer eligibility with ForesightForesight shows whether this board will consider a first-time independent director, before you spend an application.Click to get Foresight →

Independent Director — NRC and Stakeholders Relationship Committee Chair — Pharmaceutical Portfolio, Market Integrity and Patient Trust

Confidential listed pharmaceutical manufacturer Mumbai· Pharmaceuticals
Nomination & RemunerationStakeholders RelationshipAudit

Closed 29 October 2026

Scope of the seat

The Independent Director will bring operating and stakeholder judgement to a Board governing pharmaceutical research, manufacturing, regulated-market access and commercial portfolios. As Chair of the Nomination and Remuneration Committee and Stakeholders Relationship Committee, with membership of the Audit Committee, the appointee must be able to connect leadership, conduct, product responsibility and financial consequence.

The role is designed for an experienced pharmaceutical, healthcare, regulatory, commercial or enterprise leader. It does not require the Director to second-guess scientific or medical specialists. It does require the ability to test whether expert conclusions are supported, whether disagreements are escalated, and whether incentives permit inconvenient evidence to reach the Board.

Leadership succession where judgement is non-delegable

The NRC will assess the succession and performance of the chief executive and leaders responsible for research, medical affairs, quality, manufacturing, regulatory affairs, pharmacovigilance, supply, commercial markets and finance. These positions cannot be evaluated on functional targets alone; failure at their boundaries is often where the largest exposure accumulates.

The Chair will insist that succession candidates have been tested in situations involving product quality, regulator engagement, constrained supply, portfolio discontinuation, adverse evidence or a difficult market decision. High performance in stable conditions does not establish readiness for enterprise leadership.

Critical-person risk will be examined across scientific, technical and regulatory roles as well as the executive committee. The organisation should know where knowledge resides in one individual, where a release or submission depends on a fragile team, and where external advisers are substituting for institutional capability.

Incentives must preserve the right to stop

Discovery milestones, filing targets, launch dates, capacity utilisation, market share and sales can all create pressure to reinterpret weak evidence. The Director will review whether performance measures preserve the authority to pause a study, reject a batch, defer a filing, correct a claim or recall a product without destroying an individual’s career for doing the right thing.

Variable pay will balance commercial performance with quality, regulatory outcomes, patient safety, supply continuity, working capital and leadership behaviour. The committee should be able to apply downward adjustment where an outcome was achieved by accumulating a risk that emerged later.

Leadership assessment will consider the treatment of dissent. A company that celebrates scientific challenge but punishes operating challenge does not have a speak-up culture.

Stakeholder relationships in a high-consequence industry

The Stakeholders Relationship Committee will oversee more than investor-service metrics. Its agenda should integrate investors, patients, healthcare professionals, employees, regulators, distributors, research partners and communities where a material grievance may expose a wider weakness.

The Chair will require clear routes for adverse-event information, product complaints, medical-information requests, access concerns, distributor conduct, data corrections and investor grievances. Case closure must record remedy, root cause, trend and accountable prevention. Cases involving patient harm, regulatory reporting, misleading claims or retaliation must reach the appropriate Board forum quickly.

Public and investor communication about pipeline progress, approvals, shortages, remediation and market opportunity must preserve uncertainty. The Director will challenge disclosures that are literally accurate but create a stronger impression than the evidence supports.

The Audit Committee connection

As an Audit Committee member, the Director will focus on estimates and transactions whose accounting depends on scientific, regulatory or commercial judgement. These may include development expenditure, impairment, inventory expiry, product returns, chargebacks, rebates, litigation, regulatory remediation, contract manufacturing, licensing milestones and contingent consideration.

Management papers should show the underlying evidence, alternative interpretation and sensitivity—not only the preferred conclusion. Internal audit should test data lineage and decision controls across laboratories, plants, regulatory systems, safety systems, distributors and finance.

The Director will also examine whether quality and regulatory observations are translated into provisions, capacity decisions and forecast risk in a timely way. A remediation plan that exists outside the financial plan is not fully governed.

Portfolio choices and Board debate

Although this is not designated as a strategy-committee seat, the Director will contribute to portfolio decisions. The Board should understand the differentiated patient need, evidence burden, development and manufacturing dependency, commercial pathway, cash requirement and downside trigger for each material programme.

The appointee will press for explicit stop, partner or redesign criteria. Persistence is not a strategy when new evidence has changed the probability, economics or risk of success.

First six months

The incoming Director should complete structured sessions with committee chairs, auditors and leaders across quality, regulatory, medical, manufacturing, commercial and finance. Early committee work will include a leadership-depth review, a remuneration-risk test, a stakeholder escalation map and one joined-up examination of a product or market where scientific, quality, commercial and accounting judgements intersect.

Candidate profile

Applicants should have at least twenty years of senior experience in pharmaceuticals, healthcare, life sciences or a tightly regulated adjacent industry. Relevant backgrounds include enterprise leadership, regulated-market commercial responsibility, manufacturing and quality leadership, medical or regulatory affairs, finance, public policy or institutional stakeholder management.

Prior Board or committee-chair experience is strongly preferred. Applications should set out IICA Databank status, DIN (if held), regulated-industry exposure, committee history, conflicts and a concise example of a decision where protecting evidence or stakeholder trust required resisting a powerful commercial timetable.

Registration on the IICA Independent Directors Databank is required before appointment. A DIN is not needed to apply: where an appointee does not yet hold one, it is obtained through the appointing company at the point of appointment.

New to Pharma & Healthcare boards?

What these boards look for, how the committees are composed, what the seats pay, and the eligibility rules that apply.

Seats like this, open now

India ID ExchangeMedium Term

Audit Committee Chair — Digital Trust, Revenue Integrity and Platform Resilience

Confidential listed technology and trust-services company Mumbai· Technology and Digital Services
Current Listing Foresight Priority PeriodAudit Committee Chair & Financial Expert First-timer eligibilityForesight shows whether this board will consider a first-time independent director, before you spend an application.Click to get Foresight →AuditNRCCSR

The business delivers technology and trust-sensitive services. Its financial result depends on contracts, platform availability, protected information, customer acceptance and continuing service obligations. The Audit Committee Chair must therefore examine not only whether the…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 37d 20:39:55· 29 December 2026 at 11:59 pm IST
Posted 30 OctApply
India ID ExchangeMedium Term

NRC Chair and Risk Member — Listed Specialist Finance Institution

Confidential listed specialist finance institution Delhi NCR· Banking and Financial Services
Current Listing Foresight Priority PeriodSector-Regulated Independent DirectorNRCRiskStakeholders

The independent director will chair NRC and serve on Risk, Stakeholders Relationship and CSR. The mandate is to ensure that leadership, incentives and succession can withstand the institution's aggregate risk before individual businesses use their own metrics to explain it away.…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 36d 20:39:55· 28 December 2026 at 11:59 pm IST
Posted 30 OctApply
India ID ExchangeMedium Term

NRC Chair — Process Manufacturing, Succession and Long-Horizon Capability

Confidential listed process-manufacturing company Noida· Process Manufacturing
Current Listing Foresight Priority PeriodNRC Chair & Board SuccessionNRC

The company combines process engineering, manufacturing, resource stewardship, supply networks and customer relationships that mature over long cycles. The NRC Chair must ensure that leadership succession and reward preserve capability across cycles rather than optimise only the…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 35d 20:39:55· 27 December 2026 at 11:59 pm IST
Posted 29 OctApply
India ID ExchangeMedium Term

NRC Chair and Risk Member — Financial Markets Leadership and Conduct

Confidential listed financial-services company Mumbai· Banking and Financial Services
Current Listing Foresight Priority PeriodNRC Chair & Board SuccessionNRCRiskAudit

The seat chairs NRC and participates in Risk and Audit. The Board needs a director who can judge whether leadership, incentives and control-function stature support fiduciary conduct through changing markets. In financial services, stakeholder confidence can alter flows,…

Compensation status with ForesightForesight shows when compensation is not disclosed and provides a labelled benchmark where one is available.Click to get Foresight →
Apply with a free account
Applications close in 33d 20:39:55· 25 December 2026 at 11:59 pm IST
Posted 28 OctApply